A new flu vaccine using messenger RNA technology is available at some King Soopers pharmacies in Colorado, offering adults 50 ...

Moderna and Merck prepare FDA submission for their individualized mRNA melanoma vaccine.The company reported an annual ...

Profit taking is hitting one of biotech’s hottest trades, and the selling is landing heaviest on the stock that ran the ...

Stephen Hoge and Dean Li, at the STAT Summit, spoke of how Merck and Moderna will pair Keytruda with personalized mRNA ...

Moderna Inc. (NASDAQ: MRNA) has delivered an extraordinary performance in 2026, transforming from a heavily scrutinized ...

CAMBRIDGE, MA / ACCESS Newswire / October 13, 2026 / (NASDAQ:MRNA), today announced that it will host a live conference call ...

Moderna stock hit a four-year high after Goldman Sachs raised its price target on optimism about its cancer research. ・KO ...

Healthcare is drawing fresh buying as money moves away from the market’s popular technology trade, and one messenger RNA (mRNA) name is pulling well ahead of the pack. Moderna (NASDAQ:MRNA | MRNA ...

Moderna (MRNA) stock surged 14% after reports of a new NIH cancer research initiative and encouraging trial data with Merck.

Moderna, Inc. (NASDAQ:MRNA) traded at around $196 on October 7, up 4.81% on the day and 571.42% higher over twelve months.

Key TakeawaysModerna stock surged 14. 2% on October 9 after reports of an NIH-backed initiative to accelerate cancer vaccine development.

Moderna shares rose as investors welcomed its transformation into a diversified biotechnology platform.Anticipation for Phase 3 oncology trial data and new respiratory approvals drove buying pressure.